SpyGlass Pharma Inc.
SGP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SGP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SGP
SpyGlass Pharma Inc. is a pre-revenue biopharmaceutical company focused on developing product candidates for ophthalmic diseases, with no approved products and a history of operating losses.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$883.7M
Cash Runway
45.9 moLead Asset
bim-drs (Phase 3)
Next Catalyst
Phase3_Topline · Mar 31, 2031Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 6 clinical trials · 2 catalysts for SpyGlass Pharma Inc..
Similar companies
SpyGlass Pharma Inc. is a pre-revenue biopharmaceutical company focused on developing product candidates for ophthalmic diseases, with no approved products and a history of operating losses.
- SpyGlass Pharma has not generated any revenue from product sales and has incurred recurring losses since inception [sec_mda · as of 2026-08-06].
- As of June 30, 2026, the company had cash and cash equivalents and short-term investments of $234.2 million [sec_mda · as of 2026-08-06].
- Net losses were $19.9 million and $33.7 million for the three and six months ended June 30, 2026, respectively [sec_mda · as of 2026-08-06].
- Accumulated deficit was $138.4 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- The company expects operating expenses and capital expenditures to increase substantially as it advances its product candidates through clinical development [sec_mda · as of 2026-08-06].
What works
- Cash and cash equivalents and short-term investments of $234.2 million as of June 30, 2026 provide a substantial capital base to fund operations through near-term milestones [sec_mda · as of 2026-08-06].
- The company has ongoing clinical programs, including a Phase 2 study initiated in October 2023 and a Phase 1 study planned to start in July 2026, indicating active pipeline development [catalyst].
What to weigh
- The company has no approved products and has never generated revenue from product sales, with all revenue dependent on future regulatory approval [sec_mda · as of 2026-08-06].
- Accumulated deficit has grown to $138.4 million as of June 30, 2026, reflecting sustained operating losses [sec_mda · as of 2026-08-06].
- Substantial additional capital will be needed to develop product candidates and fund operations for the foreseeable future, with no guarantee of raising funds on favorable terms [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
No revenue from product sales and recurring losses
“We have not generated any revenue from product sales and we have incurred recurring losses since our inception.”
SEC MD&A · August 6, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash and cash equivalents and short-term investments of $234.2 million.”
SEC MD&A · August 6, 2026
Net loss for six months ended June 30, 2026
“Our net losses were $19.9 million and $33.7 million for the three and six months ended June 30, 2026, respectively”
SEC MD&A · August 6, 2026
Accumulated deficit as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $138.4 million.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2031-03-31 · Phase3_Topline — Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy — Topline data from a Phase 3 study expected; results will inform potential regulatory submission.
- 2031-05-31 · Phase3_Topline — Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy — Additional Phase 3 topline readout; combined data may support efficacy and safety profile.
Risks & what to watch (4)›
Key risks
- No approved products or revenue — The company has no product sales and will not generate revenue unless it obtains regulatory approval [sec_mda · as of 2026-08-06].
- Need for substantial additional capital — The company will need substantial additional funding to develop product candidates and fund operations [sec_mda · as of 2026-08-06].
- History of operating losses — Accumulated deficit of $138.4 million as of June 30, 2026, with net losses continuing [sec_mda · as of 2026-08-06].
- Clinical development uncertainty — Clinical trials may not succeed, and the company may be forced to delay or terminate programs [sec_mda · as of 2026-08-06].
What to watch
- Initiation and enrollment of the Phase 1 study (NCT07641296) expected to start July 2026 [catalyst].
- Progress and results from the ongoing Phase 2 study (NCT06120842) initiated in October 2023 [catalyst].
- Future capital raises or partnership deals to extend cash runway beyond 2028 [sec_mda · as of 2026-05-14].
- Regulatory updates and any changes in clinical trial timelines or endpoints.
Sources: Catalysts · SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run SpyGlass Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SpyGlass Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
45.9 months
D/E 0.05 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~1674d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
31
Total value held
$361.4M
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 8,021,117 | $207.8M |
| samsara biocapital, llc | 2,109,953 | $54.7M |
| vanguard capital management llc | 869,626 | $22.5M |
| deerfield management company, l.p. | 550,000 | $14.3M |
| millennium management llc | 468,794 | $12.1M |
| first light asset management, llc | 375,000 | $9.7M |
| franklin resources inc | 300,000 | $7.8M |
| affinity asset advisors, llc | 250,000 | $6.5M |
| aberdeen group plc | 220,454 | $5.7M |
| blackrock, inc. | 144,739 | $3.8M |
Showing top 10 of 31 institutional holders of SpyGlass Pharma Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 8.0%
- Days to cover
- 11.8
- Shares short
- 884,597
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SGP short interestFrequently asked questions
What is the AI investment thesis for SpyGlass Pharma Inc.?
SpyGlass Pharma Inc. is a pre-revenue biopharmaceutical company focused on developing product candidates for ophthalmic diseases, with no approved products and a history of operating losses.
What is SpyGlass Pharma Inc.'s lead drug candidate?
SpyGlass Pharma Inc.'s most advanced tracked candidate is bim-drs (Phase 3) for Glaucoma.
What is SpyGlass Pharma Inc.'s next catalyst?
SpyGlass Pharma Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety and Efficacy" — expected March 31, 2031.
Who is the CEO of SpyGlass Pharma Inc.?
Mr. Patrick H. Mooney is the chief executive officer of SpyGlass Pharma Inc. (SGP).
Where is SpyGlass Pharma Inc. headquartered?
SpyGlass Pharma Inc. (SGP) is headquartered in Aliso Viejo, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.